share_log

Assure | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Assure | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Assure | 425：募资说明/企业合并公告
美股SEC公告 ·  05/21 12:46
Moomoo AI 已提取核心信息
Assure Holdings Corp., a provider of intraoperative neuromonitoring and remote neurology services, announced significant corporate developments in a series of press releases and SEC filings. On April 8, 2024, the company's Board of Directors approved an amendment to increase the authorized shares of common stock from 9 million to 250 million, which was subsequently approved by stockholders on May 14, 2024. The Certificate of Amendment was filed with the State of Nevada on May 17, 2024, to effectuate the increase. Additionally, Assure received a decision from the Nasdaq Hearings Panel on May 16, 2024, granting an extension until July 22, 2024, to regain compliance with Nasdaq's listing requirements in light of its upcoming transaction with Danam Health Inc. The company also scheduled a webinar presentation for stockholders and investors on May 17, 2024. These announcements are part of Assure's ongoing efforts to complete a proposed transaction with Danam Health Inc., for which a registration statement containing a prospectus and a proxy statement was filed with the SEC on May 3, 2024. The transaction is subject to stockholder approval and other customary closing conditions.
Assure Holdings Corp., a provider of intraoperative neuromonitoring and remote neurology services, announced significant corporate developments in a series of press releases and SEC filings. On April 8, 2024, the company's Board of Directors approved an amendment to increase the authorized shares of common stock from 9 million to 250 million, which was subsequently approved by stockholders on May 14, 2024. The Certificate of Amendment was filed with the State of Nevada on May 17, 2024, to effectuate the increase. Additionally, Assure received a decision from the Nasdaq Hearings Panel on May 16, 2024, granting an extension until July 22, 2024, to regain compliance with Nasdaq's listing requirements in light of its upcoming transaction with Danam Health Inc. The company also scheduled a webinar presentation for stockholders and investors on May 17, 2024. These announcements are part of Assure's ongoing efforts to complete a proposed transaction with Danam Health Inc., for which a registration statement containing a prospectus and a proxy statement was filed with the SEC on May 3, 2024. The transaction is subject to stockholder approval and other customary closing conditions.
术中神经监测和远程神经病学服务提供商Assure Holdings Corp. 在一系列新闻稿和美国证券交易委员会文件中宣布了公司的重大进展。2024 年 4 月 8 日，公司董事会批准了一项修正案，将普通股的授权股数从 900 万股增加到 2.5 亿股，该修正案随后于 2024 年 5 月 14 日获得股东的批准。修正证书于2024年5月17日向内华达州提交，以使上调生效。此外，鉴于即将与达南健康公司进行交易，Assure于2024年5月16日收到纳斯达克听证会小组的决定，批准将期限延长至2024年7月22日，以恢复对纳斯达克上市要求的遵守。该公司还计划于2024年5月17日为股东和投资者举办一次网络研讨会演讲。这些公告是Assure为完成与Danam Health Inc.的拟议交易所做的持续努力的一部分，该交易的注册声明已于2024年5月3日向美国证券交易委员会提交了包含招股说明书和委托书的注册声明。该交易须经股东批准和其他惯例成交条件。
术中神经监测和远程神经病学服务提供商Assure Holdings Corp. 在一系列新闻稿和美国证券交易委员会文件中宣布了公司的重大进展。2024 年 4 月 8 日，公司董事会批准了一项修正案，将普通股的授权股数从 900 万股增加到 2.5 亿股，该修正案随后于 2024 年 5 月 14 日获得股东的批准。修正证书于2024年5月17日向内华达州提交，以使上调生效。此外，鉴于即将与达南健康公司进行交易，Assure于2024年5月16日收到纳斯达克听证会小组的决定，批准将期限延长至2024年7月22日，以恢复对纳斯达克上市要求的遵守。该公司还计划于2024年5月17日为股东和投资者举办一次网络研讨会演讲。这些公告是Assure为完成与Danam Health Inc.的拟议交易所做的持续努力的一部分，该交易的注册声明已于2024年5月3日向美国证券交易委员会提交了包含招股说明书和委托书的注册声明。该交易须经股东批准和其他惯例成交条件。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息